Sedative-hypnotic use disorder encompasses benzodiazepines, z-drugs (zolpidem and similar), barbiturates, and other GABA-enhancing agents. The disorder is often iatrogenic — patients prescribed these medications for anxiety, insomnia, or muscle spasm who develop tolerance, dependence, and difficulty discontinuing.
Iatrogenic dependence is the most common pattern. A patient prescribed alprazolam for panic disorder in their thirties, escalating dose over years, finds themselves unable to function without it in their fifties. They did not seek out a substance; the substance was prescribed. The dependence pattern is real regardless of how it began.
Sedative-hypnotic withdrawal can be fatal. Withdrawal mirrors alcohol withdrawal: tremor, anxiety, insomnia, autonomic instability, and at severe levels seizures and delirium. Mortality risk substantially elevated, particularly with abrupt discontinuation of high-dose, long-duration use. Tapering, not abrupt discontinuation, is mandatory.
The taper approach:
(1) Switch short-acting to long-acting if not already on one. Short-acting benzodiazepines (alprazolam, lorazepam) produce inter-dose withdrawal that complicates tapering. Switch to diazepam or clonazepam at equivalent dose for smoother taper.
(2) Reduce slowly. 5-10% dose reduction every 2-4 weeks is the typical cadence. Long-duration high-dose use may require slower tapers — total taper duration of 6-18 months not unusual for sustained high-dose alprazolam users.
(3) Combine with behavioral intervention. CBT for insomnia or anxiety addresses the underlying conditions the patient was originally medicated for. Without this work, the patient will rebound on cessation and the taper will fail.
(4) Monitor closely. Monthly clinical contact during taper. Address sleep, anxiety, irritability as they emerge. Hold the taper or back up slightly during severe symptoms; rushing tends to produce treatment failure.
The Ashton protocol is one structured, evidence-informed approach widely used by clinicians experienced in benzodiazepine taper.
Z-drugs (zolpidem, zaleplon, eszopiclone) share GABA-A modulation with benzodiazepines and produce similar dependence and withdrawal patterns. Patients sometimes believe z-drugs are "safer" than benzodiazepines; the long-term dependency pattern is comparable. Tolerance often develops within weeks of nightly use.
Barbiturates are now rarely prescribed for primary sedative use given safer alternatives but still appear in headache management (butalbital combinations), some seizure disorders, and anesthesia. Same taper principles apply.
When you encounter a patient on long-term sedative-hypnotic therapy who wants to taper, the work is real and takes time. Resist pressure to rush. Combine with behavioral treatment of the underlying condition. The patient who has been on alprazolam for 10 years will not be off it in 6 weeks — and shouldn't be.